Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(56%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
7
78%
Ph phase_1
1
11%
Ph phase_2
1
11%

Phase Distribution

1

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
7(77.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(2)

Detailed Status

Active, not recruiting4
Completed2
Enrolling by invitation2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 37 (77.8%)

Trials by Status

active_not_recruiting444%
completed222%
enrolling_by_invitation222%
recruiting111%

Recent Activity

5 active trials
Showing 5 of 9
active_not_recruitingphase_3

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

NCT06768671
enrolling_by_invitationphase_3

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637
recruitingphase_3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089
active_not_recruitingphase_3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
enrolling_by_invitationphase_3

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

NCT07223138
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06768671Phase 3

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Active Not Recruiting
NCT07007637Phase 3

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Enrolling By Invitation
NCT06641089Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Recruiting
NCT06641076Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Active Not Recruiting
NCT07223138Phase 3

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Enrolling By Invitation
NCT06994936Phase 1

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Completed
NCT06411379Phase 3

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Active Not Recruiting
NCT06411899Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Active Not Recruiting
NCT05640245Phase 2

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9